Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

  • Condition: Non-Small Cell Lung Cancer (NSCLC)
  • Journal: BMC pulmonary medicine
  • Treatment Used: Immune Checkpoint Inhibitors (ICIs)
  • Number of Patients: 175
  • Published —
This study determined the effectiveness of checkpoint inhibitors (ICIs) for the treatment of patients with non-small cell lung cancer (NSCLC) with uncommon histology (uNSCLC).
  • Condition: Large cell neuroendocrine carcinoma (LCNEC) of Lungs
  • Journal: Annals of palliative medicine
  • Treatment Used: Surgery, Radiotherapy, Chemotherapy, and Immunotherapy
  • Number of Patients: 1
  • Published —
This case report describes a 64-year-old male smoker diagnosed with pulmonary large cell neuroendocrine carcinoma (LCNEC) treated with thoracoscopic radical surgery, postoperative chemotherapy with a double-drug regimen holding platinum, and then, bevacizumab, paclitaxel, and the PD-L1 checkpoint inhibitor nivolumab.
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 30
  • Start Date: December 1, 2020
Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy :a Single-arm Phase II Trial
Clinical Trial
  • Status: Recruiting
  • Phase: N/A
  • Intervention Type: Other, Drug, Biological
  • Participants: 8300
  • Start Date: August 18, 2014
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)